Trial Profile
A pilot study to compare different glycoforms of the CAMPATH-1H (alemtuzumab CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Oct 2005
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 25 Oct 2005 New trial record.